Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01700049 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01700049: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01700049 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01700049, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'histologic subtypes' of basal cell skin cancer (infiltrative/morpheaform, nodular and superficial) will be examined in this study.
Interventions
- DRUG vismodegib (150 mg PO daily)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-01-14 |
| Est. Completion | 2018-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01700049
The ClinicalTrials.gov registry entry for NCT01700049 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vismodegib (150 mg PO daily) is the first listed.
NCT01700049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01700049 about?
NCT01700049 is a clinical study titled "Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes". The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different ...
What is the current status of trial NCT01700049?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2013-01-14. Estimated completion is 2018-07-03.
What interventions are being tested in trial NCT01700049?
The interventions under investigation include: vismodegib (150 mg PO daily) (DRUG).
Who is sponsoring clinical trial NCT01700049?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.